X
LAB icon

Xponance’s Standard BioTools LAB Stock Holding History

Xponance’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.9K Buy
27,043
+3,446
+15% +$4.17K ﹤0.01% 1666
2025
Q4 		$30.2K Buy
23,597
+195
+0.8% +$262 ﹤0.01% 1553
2025
Q3 		$30.4K Hold
23,402
– – ﹤0.01% 1510
2025
Q2 		$28.1K Buy
23,402
+2,024
+9% +$2.24K ﹤0.01% 1486
2025
Q1 		$23.1K Buy
21,378
+1,103
+5% +$1.55K ﹤0.01% 1420
2024
Q4 		$35.5K Buy
20,275
+1,771
+10% +$3.3K ﹤0.01% 1413
2024
Q3 		$35.7K Sell
18,504
-639
-3% -$1.25K ﹤0.01% 1363
2024
Q2 		$33.9K Buy
+19,143
New +$46.8K ﹤0.01% 1291

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Xponance's LAB Position: Q1 2026 in Review

Xponance increased its Standard BioTools (LAB) stake by 15% in Q1 2026, buying an estimated $4.17K and bringing the position to 27,043 shares worth $24.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1666.

Xponance first reported a position in LAB in Q2 2024 and has held it in 8 quarters since. The position peaked at $35.7K in Q3 2024. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • Xponance held 27,043 shares of Standard BioTools worth $24.9K as of Q1 2026.
  • Xponance bought 3,446 Standard BioTools shares in Q1 2026, an estimated $4.17K.
  • Standard BioTools made up ﹤0.01% of Xponance's portfolio in Q1 2026, its #1666 holding.
  • Xponance first reported a position in Standard BioTools in Q2 2024 and has held it in 8 quarters since.
  • Xponance's Standard BioTools position peaked at $35.7K in Q3 2024.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.